Pesquisar
AIM ImmunoTech Inc
AIMAdicionar à lista de desejos
0.251USD
-0.007-2.56%
Horário de mercado （ET）Cotações atrasadas em 15 min
772.54KValor de mercado
PerdaP/L TTM
Mais detalhes de AIM ImmunoTech Inc Empresa
AIM ImmunoTech Inc. is an immuno-pharma company. The Company is focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases, including COVID-19. The Company’s flagship products are Ampligen (rintatolimod) and Alferon N Injection (Interferon alfa). Ampligen is a double-stranded RNA (dsRNA) and highly selective TLR3 agonist immuno-modulator, which is being developed for globally important cancers, viral diseases and disorders of the immune system. Ampligen is approved for commercial sale in the Argentine Republic for the treatment of severe chronic fatigue syndrome (CFS). Alferon N Injection is an injectable formulation of natural alpha interferon, which is approved for sale in the United States and Argentina for the intralesional treatment of refractory or recurring external genital warts in patients 18 years of age or older.
Informações de AIM ImmunoTech Inc
Código da empresaAIM
Nome da EmpresaAIM ImmunoTech Inc
Data de listagemJul 12, 1996
CEOEquels (Thomas K)
Número de funcionários21
Tipo de títulosOrdinary Share
Fim do ano fiscalJul 12
Endereço2117 Sw Highway 484
CidadeOCALA
Bolsa de valoresNASDAQ OMX – NASDAQ Basic Amex
PaísUnited States of America
Código postal32801
Telefone13524487797
Sitehttps://aimimmuno.com/
Código da empresaAIM
Data de listagemJul 12, 1996
CEOEquels (Thomas K)
Executivos da empresa AIM ImmunoTech Inc
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Thomas K. Equels, Esq., J.D.
Mr. Thomas K. Equels, Esq., J.D.
President, Chief Executive Officer, Executive Vice Chairman of the Board
President, Chief Executive Officer, Executive Vice Chairman of the Board
63.92K
+39.13%
Mr. David I. Chemerow
Mr. David I. Chemerow
Independent Director
Independent Director
28.44K
+97.74%
Dr. William M. Mitchell, M.D., Ph.D.
Dr. William M. Mitchell, M.D., Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
5.22K
+0.04%
Ms. Nancy K. Bryan
Ms. Nancy K. Bryan
Independent Director
Independent Director
2.92K
-0.03%
Mr. Robert (Rob) Dickey, IV
Mr. Robert (Rob) Dickey, IV
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Peter W. Rodino, III
Mr. Peter W. Rodino, III
Chief Operating Officer, Executive Director - Governmental Relations, General Counsel, Company Secretary
Chief Operating Officer, Executive Director - Governmental Relations, General Counsel, Company Secretary
--
--
Ms. Jenene Thomas
Ms. Jenene Thomas
Investor Relations
Investor Relations
--
--
Mr. Ted D. Kellner
Mr. Ted D. Kellner
Independent Director
Independent Director
--
--
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Thomas K. Equels, Esq., J.D.
Mr. Thomas K. Equels, Esq., J.D.
President, Chief Executive Officer, Executive Vice Chairman of the Board
President, Chief Executive Officer, Executive Vice Chairman of the Board
63.92K
+39.13%
Mr. David I. Chemerow
Mr. David I. Chemerow
Independent Director
Independent Director
28.44K
+97.74%
Dr. William M. Mitchell, M.D., Ph.D.
Dr. William M. Mitchell, M.D., Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
5.22K
+0.04%
Ms. Nancy K. Bryan
Ms. Nancy K. Bryan
Independent Director
Independent Director
2.92K
-0.03%
Mr. Robert (Rob) Dickey, IV
Mr. Robert (Rob) Dickey, IV
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Peter W. Rodino, III
Mr. Peter W. Rodino, III
Chief Operating Officer, Executive Director - Governmental Relations, General Counsel, Company Secretary
Chief Operating Officer, Executive Director - Governmental Relations, General Counsel, Company Secretary
--
--
Detalhamento da receita
Os dados relevantes ainda não foram divulgados pela empresa.
Os dados relevantes ainda não foram divulgados pela empresa.
Por Empresa
Por Região
Os dados relevantes ainda não foram divulgados pela empresa.
Distribuição de ações
Atualizado em: qui, 14 de mai
Atualizado em: qui, 14 de mai
Investidores
Tipos de investidores
Investidores
Investidores
Proporção
DRW Securities, LLC
0.85%
Equels (Thomas K)
0.78%
Kellner (Theodore D)
0.46%
Chemerow (David I)
0.35%
Jane Street Capital, L.L.C.
0.25%
Outro
97.31%
Investidores
Investidores
Proporção
DRW Securities, LLC
0.85%
Equels (Thomas K)
0.78%
Kellner (Theodore D)
0.46%
Chemerow (David I)
0.35%
Jane Street Capital, L.L.C.
0.25%
Outro
97.31%
Tipos de investidores
Investidores
Proporção
Individual Investor
2.00%
Investment Advisor
1.08%
Investment Advisor/Hedge Fund
0.21%
Outro
96.70%
Participação acionária institucional
Atualizado em: qua, 1 de abr
Atualizado em: qua, 1 de abr
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2026Q1
57
105.74K
1.30%
-74.29K
2025Q4
56
107.25K
2.64%
--
2025Q3
59
107.25K
2.79%
+95.13K
2025Q2
58
12.12K
12.55%
-36.20K
2025Q1
67
48.31K
13.00%
-45.65K
2024Q4
64
46.48K
14.87%
-43.65K
2024Q3
61
90.13K
15.18%
+5.69K
2024Q2
61
84.44K
8.12%
+43.50K
2024Q1
64
40.95K
9.51%
-6.49K
2023Q4
65
41.55K
9.71%
-1.72K
Ver Mais
Atividade dos acionistas
Nome
Ações detidas
Proporção
Variação
Var. %
Data
DRW Securities, LLC
69.61K
0.85%
+26.28K
+60.65%
Dec 31, 2025
Equels (Thomas K)
63.92K
0.78%
+25.01K
+64.29%
Mar 25, 2026
Kellner (Theodore D)
37.24K
0.46%
-2.00
-0.01%
Mar 25, 2026
Chemerow (David I)
28.44K
0.35%
+27.80K
+4330.06%
Mar 25, 2026
Geode Capital Management, L.L.C.
17.39K
0.21%
+1.19K
+7.35%
Dec 31, 2025
Deutsch (Todd A)
17.18K
0.21%
--
--
Dec 19, 2024
Mitchell (William M)
5.22K
0.06%
+2.00
+0.04%
Mar 25, 2026
Rodino (Peter W III)
4.02K
0.05%
+3.00
+0.07%
Mar 25, 2026
Ver Mais
ETFs Relacionados
Atualizado em: sáb, 6 de dez
Atualizado em: sáb, 6 de dez
Nome
Proporção
iShares Core S&P Total U.S. Stock Market ETF
0%
iShares Core S&P Total U.S. Stock Market ETF
Proporção0%
Dividendo
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Sem dados
Desdobramento de ações
Data
Data ex-dividendo
Tipo
Proporção
Mar 03, 2025
Merger
100→1
Data
Data ex-dividendo
Tipo
Proporção
Mar 03, 2025
Merger
100→1
